MAPK3 and depressive disorder: Other investigations into the etiopathogenesis of depression-like behavior have revealed a connection between p-ERK1/2 and depressed symptoms and the ability of antidepressants, such as ketamine, to lessen depressive symptoms by enhancing p-ERK1/2 expression18.